XTL Biopharmaceuticals Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
XTL Biopharma (XTLB) Reports Breakeven Q2 Loss
September 1, 2015 9:20 AM EDTXTL Biopharma (NASDAQ: XTLB) reported Q2 loss of $0.00, versus $0.00 reported last year.
Following XTL's registered direct offering in April, 2015, XTL had US$4.8 million in cash and cash equivalents as of June 30, 2015.
For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.
... More